Press Release

Printer Friendly Version View printer-friendly version
<< Back

Histogenics Announces Nancy Lynch, M.D., as CMO

10/28/13

Orthopedic Surgeon and Venture Capitalist Brings Extensive Experience In Orthopedic Innovation

Waltham, Mass. – October 28, 2013BUSINESS WIRE –Histogenics Corp., a biologics company leveraging the latest advances in bioengineering, proprietary materials science and molecular and cellular biology develop novel tissue repair solutions, today announced the appointment of Nancy Lynch, M.D., as its Chief Medical Officer.

“Nancy’s expertise as both a surgeon and collaborator in the entrepreneurial arena of orthopedics makes her a perfect fit for this important role at Histogenics”

Dr. Lynch has over 25 years of experience in the clinical and business elements of orthopedics, as both a Board-certified, fellowship-trained orthopedic surgeon and venture capitalist. Prior to joining Histogenics, she founded Advisorthopædics, where she focused exclusively on innovation in orthopedics, providing consultation services to many organizations developing products for musculoskeletal care. Previously, after receiving an M.B.A. from Duke University’s Fuqua School of Business, Dr. Lynch held positions at Scale Venture Partners and the Aurora Funds. Before transitioning to a career in business, she pursued her surgical training in orthopedics at the Mayo Clinic, completed additional fellowship training in the U.S. and Switzerland, then practiced full time for several years at Orthopedic Healthcare Northwest. She earned her M.D. from the Washington University School of Medicine in St. Louis. Dr. Lynch is a Fellow of the American Academy of Orthopaedic Surgeons.

“Nancy’s expertise as both a surgeon and collaborator in the entrepreneurial arena of orthopedics makes her a perfect fit for this important role at Histogenics,” said Histogenics’ Chief Executive Officer, Peter Greenleaf. “Our lead product candidate, NeoCart, is in late-stage development and will benefit greatly from Nancy’s experience as we move closer to the finish line.”
“With its core technologies in novel tissue repair and, in particular, its near-term candidate opportunity in NeoCart, Histogenics is well-positioned to usher in a new era of medicine,” said Dr. Lynch. “I am very excited to join this team and this company in its pursuit of transformative solutions addressing critically important unmet needs in tissue repair.”

About Histogenics
Histogenics is a biologics company and an emerging leader in the development of novel tissue repair solutions. We leverage a combination of the latest advances in bioengineering, proprietary materials science and molecular and cellular biology to create breakthrough products that help improve patient outcomes. Our lead product program, NeoCart®, is a personalized cartilage tissue implant.